公开(公告)号：US20180271069A1

公开(公告)日：2018-09-27

申请号：US15914728

申请日：2018-03-07

Applicant: The Board of Regents of the University of Texas System

Inventor： Yi-Li MIN ,  Rhonda BASSEL-DUBY ,  Eric OLSON

IPC: A01K67/027 ,  C12N9/22 ,  C12N9/96 ,  C12N15/11 ,  A61K38/46 ,  A61K31/7105 ,  A61P21/00

Abstract: Duchenne muscular dystrophy (DMD), which affects 1 in 5,000 male births, is one of the most common genetic disorders of children. This disease is caused by an absence or deficiency of dystrophin protein in striated muscle. The major DMD deletion “hot spots” are found between exon 6 to 8, and exons 45 to 53. Here, a “humanized” mouse model is provided that can be used to test a variety of DMD exon skipping strategies. Among these are, CRISPR/Cas9 oligonucleotides, small molecules or other therapeutic modalities that promote exon skipping or micro dystrophin mini genes or cell based therapies. Methods for restoring the reading frame of exon 44 deletion via CRISPR-mediated exon skipping in the humanized mouse model, in patient-derived iPS cells and ultimately, in patients using various delivery systems are also contemplated. The impact of CRISPR technology on DMD is that gene editing can permanently correct mutations.

公开(公告)号：US20210261962A1

公开(公告)日：2021-08-26

申请号：US17253606

申请日：2019-06-21

Applicant: The Board of Regents of the University of Texas System

Inventor： Yi-Li MIN ,  Rhonda BASSEL-DUBY ,  Eric OLSON

IPC: C12N15/113 ,  C12N9/22 ,  C12N15/86 ,  A01K29/00

Abstract: Duchenne muscular dystrophy (DMD), which affects 1 in 5,000 male births, is one of the most common genetic disorders of children. This disease is caused by an absence or deficiency of dystrophin protein in striated muscle. The major DMD deletion “hot spots” are found between exon 6 to 8, and exons 45 to 53. Here, three DMD mouse models are provided that can be used to test a variety of DMD exon skipping and refraining strategies. Among these are, CRISPR/Cas9 oligonucleotides, small molecules or other therapeutic modalities that promote exon skipping or exon refraining or micro dystrophin mini genes or cell based therapies. Methods for restoring the reading frame of exon 43, exon 45, and exon 52 deletion via CRISPR-mediated exon skipping and refraining in the humanized DMD mouse model, in patient-derived iPSCs and ultimately, in patients using various delivery systems are also contemplated. The impact of CRISPR technology on DMD is that gene editing can permanently correct mutations.

公开(公告)号：US20200275641A1

公开(公告)日：2020-09-03

申请号：US15930781

申请日：2020-05-13

Applicant: The Board of Regents of the University of Texas System

Inventor： Yi-Li MIN ,  Rhonda BASSEL-DUBY ,  Eric OLSON

IPC: A01K67/027 ,  C12N9/22 ,  C12N9/96 ,  C12N15/11 ,  A61K38/46 ,  A61K31/7105 ,  A61P21/00 ,  C12N15/113

Abstract: Duchenne muscular dystrophy (DMD), which affects 1 in 5,000 male births, is one of the most common genetic disorders of children. This disease is caused by an absence or deficiency of dystrophin protein in striated muscle. The major DMD deletion “hot spots” are found between exon 6 to 8, and exons 45 to 53. Here, a “humanized” mouse model is provided that can be used to test a variety of DMD exon skipping strategies. Among these are, CRISPR/Cas9 oligonucleotides, small molecules or other therapeutic modalities that promote exon skipping or micro dystrophin mini genes or cell based therapies. Methods for restoring the reading frame of exon 44 deletion via CRISPR-mediated exon skipping in the humanized mouse model, in patient-derived iPS cells and ultimately, in patients using various delivery systems are also contemplated. The impact of CRISPR technology on DMD is that gene editing can permanently correct mutations.